If you have significant diabetes or weight-related health issues, the benefits to your health might outweigh the small theoretical risks
In head-to-head comparison during the STEP trials, semaglutide 2.4 mg weekly produced significantly greater weight reduction than liraglutide 3.0 mg daily, approximately 15% versus 7% of body weight over similar timeframes
Treatment discontinuation due to side effects occurred in 4.3%, 7.1%, 6.2%, and 2.6% of participants in the 5, 10, 15 mg, and placebo groups, respectively [18]
Comparative analysis revealed that oral administration is more likely to induce gastrointestinal disorders such as pancreatitis, pancreatic cancer, belching, gastric emptying disorders, and gallstones when compared to subcutaneous injection
Understanding these elements helps patients approach their care with awareness and preparedness